Cerebral folate deficiency and CNS inflammatory markers in Alpers disease
- PMID: 19766516
- DOI: 10.1016/j.ymgme.2009.08.005
Cerebral folate deficiency and CNS inflammatory markers in Alpers disease
Abstract
We describe a 3.5-year-old female with Alpers disease with a POLG genotype of p.A467T/p.G848S and with a lethal outcome. Laboratory investigation revealed elevated CSF neopterin, IL-6, IL-8, IFN-gamma, reduced CSF 5-methyltetrahydrofolate (5MTHF), and increased serum as well as CSF folate receptor blocking autoantibodies. Treatment with oral Leucovorine (5-formyl-tetrahydrofolate) was initiated at 0.25mg/kg bid, and later increased to 4mg/kg bid. Under treatment CSF levels of 5MTHF, seizure frequency and communicative abilities improved. Over a time span of 17months, CSF levels of IL-6 and IFN-gamma decreased, levels of folate receptor blocking autoantibodies continued to raise, whereas CSF IL-8 remained elevated 1500-fold above normal. The child died without apparent stress at the age of 5.5years. Alpers disease, a neurodegenerative disease usually presents in the first years of life as a progressive encephalopathy with multifocal myoclonic seizures, developmental regression, cortical blindness and early death. The underlying genetic defect has been attributed to mutations of the catalytic subunit of the mitochondrial DNA polymerase-gamma leading to an organ-specific mitochondrial DNA depletion syndrome with reduced activity of respiratory chain enzyme complexes in the brain and the liver. A curative therapy is not available. This case report of Alpers disease provides new insights into the pathophysiology of Alpers disease, where mitochondrial dysfunction in conjunction with inflammatory cytokines and blocking folate receptor autoantibodies may lead to a secondary cerebral folate deficiency syndrome. The treatment of the latter provides relief to the patient without stopping the underlying disease.
Similar articles
-
Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits.Neuropediatrics. 2007 Dec;38(6):276-81. doi: 10.1055/s-2008-1065354. Neuropediatrics. 2007. PMID: 18461502
-
Autoantibodies to folate receptors in the cerebral folate deficiency syndrome.N Engl J Med. 2005 May 12;352(19):1985-91. doi: 10.1056/NEJMoa043160. N Engl J Med. 2005. PMID: 15888699
-
POLG1 mutations associated with progressive encephalopathy in childhood.J Neuropathol Exp Neurol. 2006 Aug;65(8):758-68. doi: 10.1097/01.jnen.0000229987.17548.6e. J Neuropathol Exp Neurol. 2006. PMID: 16896309
-
Clinical recognition and aspects of the cerebral folate deficiency syndromes.Clin Chem Lab Med. 2013 Mar 1;51(3):497-511. doi: 10.1515/cclm-2012-0543. Clin Chem Lab Med. 2013. PMID: 23314536 Review.
-
Consequences of mutations in human DNA polymerase gamma.Gene. 2005 Jul 18;354:125-31. doi: 10.1016/j.gene.2005.03.029. Gene. 2005. PMID: 15913923 Review.
Cited by
-
Cerebral Folate Metabolism in Post-Mortem Alzheimer's Disease Tissues: A Small Cohort Study.Int J Mol Sci. 2022 Dec 30;24(1):660. doi: 10.3390/ijms24010660. Int J Mol Sci. 2022. PMID: 36614107 Free PMC article.
-
POLG-related disorders and their neurological manifestations.Nat Rev Neurol. 2019 Jan;15(1):40-52. doi: 10.1038/s41582-018-0101-0. Nat Rev Neurol. 2019. PMID: 30451971 Free PMC article. Review.
-
Therapy Prospects for Mitochondrial DNA Maintenance Disorders.Int J Mol Sci. 2021 Jun 16;22(12):6447. doi: 10.3390/ijms22126447. Int J Mol Sci. 2021. PMID: 34208592 Free PMC article. Review.
-
Epidemiology and natural history of POLG disease in Norway: a nationwide cohort study.Ann Clin Transl Neurol. 2024 Jul;11(7):1819-1830. doi: 10.1002/acn3.52088. Epub 2024 Jun 7. Ann Clin Transl Neurol. 2024. PMID: 38845467 Free PMC article.
-
Cerebral folate deficiency.J Inherit Metab Dis. 2010 Oct;33(5):563-70. doi: 10.1007/s10545-010-9159-6. Epub 2010 Jul 29. J Inherit Metab Dis. 2010. PMID: 20668945 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical